SCHEMBL2134416

SCHEMBL2134416

CCOC(=O)/C=C/c1cn(C)c2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.61
KMT2A Q03164 4/20 0.61
MAPT P10636 3/20 0.61
NPC1 O15118 2/20 0.61
RAB9A P51151 2/20 0.61
CASP3 P42574 1/20 0.61
SENP8 Q96LD8 1/20 0.61
SENP7 Q9BQF6 1/20 0.61
SENP6 Q9GZR1 1/20 0.61
ATM Q13315 1/20 0.58
ALDH1A1 P00352 5/20 0.57
HPGD P15428 2/20 0.57
LMNA P02545 1/20 0.57
PRKCA P17252 3/20 0.56
PRKCE Q02156 3/20 0.56
RASGRP3 Q8IV61 3/20 0.56
IMPDH2 P12268 1/20 0.51
NR4A2 P43354 1/20 0.47
GAA P10253 1/20 0.45
KDM4E B2RXH2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22713034 0.86 KMT2A (0.68) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL23600586 0.85 MEN1 (0.66) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL10629219 0.82 BACE1 (0.58) MEN1KMT2AMAPTATMALDH1A1
SCHEMBL10629344 0.82 BACE1 (0.58) MEN1KMT2AMAPTATMALDH1A1
SCHEMBL4580067 0.82 ATM (0.48) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL15984842 0.82 KMT2A (0.66) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL23046854 0.81 KMT2A (0.69) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL10781557 0.81 ABCG2 (0.57) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL8494191 0.81 KMT2A (0.73) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL8494188 0.81 KMT2A (0.73) MEN1KMT2AMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11485725-B2 Derivatives of piperlongumine and uses thereof AURANSA INC. (US) 2022-11-01 US disclosed
US-20200377510-A1 DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF AURANSA INC. 2020-12-03 US disclosed
US-20120101105-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200377510-A1 DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF SHARPIN, PIR, THPO MEN1 1134/4885KMT2A 2446/4885MAPT 2707/4885
US-20120101105-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS CACNA1I, CACNA1G, CACNA1H MEN1 3635/4885KMT2A 1764/4885MAPT 2691/4885
US-11485725-B2 Derivatives of piperlongumine and uses thereof PIR, THPO, DHPS MEN1 1372/4885KMT2A 2612/4885MAPT 2454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.